Dina D. Demchenko

Dina D. Demchenko

Auto-generated profile, based on publicly available information

Dina D. Demchenko

Saint Petersburg State Chemical-Pharmaceutical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2020 in Pharmacy Formulas
Verified
Journal Article
Open access
INIgor A. Narkevich
Igor A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
VTViladimir Timchenko
Viladimir Timchenko
DSDina D. Siukaeva
Dina D. Siukaeva
TTTaisia M. Terninko
Taisia M. Terninko
VAVasilina A. Alekseeva
Vasilina A. Alekseeva
The purpose evaluated the range of drugs for the etiopathogenetic treatment of children with acute viral infections. The methods of content analysis, data aggregation, comparative analysis are used. The research information base was made up of State Register of Medicines and National Registry of Medicines data as of 26 November 2019, as well as instructions for the medical use of drugs. It is shown that in the Russian Federation 201 trade names of drugs (35 INN) and 57 substances are registered. The leading positions in the structure of the supply of drugs and substances are held by russian manufacturers (76,00% and 70,00%, respectively). At the same time, structuring by dosage forms allows one to isolate tablets and powders (39,00% and 78,00% for finished dosage forms and substances, respectively). Acyclovir prevails in the structure of the range of medicines (25,00% and 19,00% for international non-proprietary and trade names, respectively). The largest share in the structure of the assortment of substances is covered by interferon alfa-2b (17,50%). The results of the analysis demonstrate that for most drugs, the manufacturer carries out all stages of production, including issuing quality control (67,00%). For 2015-2019, the renewal index of the assortment of the study group was 22,38%. Given the uncontrolled increase in the incidence rate, the presented assortment of antiviral and immunomodulating agents is sufficient to satisfy the needs of Russian pediatrics. One of the promising vectors for the development of the pharmaceutical industry in terms of providing medicines for children with acute viral infections is the development of drugs in the form of children's corrected forms.

2 December 2020 in Pharmacy Formulas
Verified
Journal Article
Open access
INIgor A. Narkevich
Igor A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
DSDina D. Siukaeva
Dina D. Siukaeva
ETEvgenia A. Tsitlionok
Evgenia A. Tsitlionok
VLValeria O. Lisacenco
Valeria O. Lisacenco
AGAnastassiya S. Grinyuk
Anastassiya S. Grinyuk
The article presents a study on the structural assessment of the range of drugs for the treatment of hepatitis C. Methods of content analysis, data aggregation, grouping, comparative and marketing analysis have been used. The information base of the study was the State Register of Medicines and National Register of Medicines of April 24, 2020, as well as instructions for the medical use of drugs. It was revealed that 52 trade names of medicinal products (23 INN) and 17 substances had been registered in the Russian Federation. The analysis carried out by pharmaceutical producing countries has shown that the leading positions in the supply structure are occupied by Russian manufacturers (73.08%). Structuring by dosage forms enables to isolate tablets, covering 32.69%, as well as solutions and capsules, which are 23.08%, respectively. The largest share in the structure of the assortment of substances is occupied by interferon alpha-2b (20.93%). The results of the analysis has shown that the manufacturer carries out all stages of production for the majority of drugs. The index of renewal of the researched drug market over the past 5 years is 16.27%.

Verified
Journal Article
Open access
PDF file
ONOksana Nemyatykh
Oksana Nemyatykh
МММарина Майстренко
Марина Майстренко
DDDina D. Demchenko
Dina D. Demchenko
INIgor A. Narkevich
Igor A. Narkevich
SOSergey Okovityi
Sergey Okovityi
VTViladimir Timchenko
Viladimir Timchenko
The purpose of this review was to conduct a comparative assessment of the concepts of therapy for pediatric patients with COVID-19 in the framework of global clinical practice. A structural analysis of the range of drugs and treatment strategies in the context of etiotropic, pathogenetic, and symptomatic therapy has shown that in the global context and in real clinical practice, the etiotropic-pathogenetic approach based on information about the effectiveness of individual medical technologies prevails today. It has been established that eight international nonproprietary/grouping names are present in international practice as means of etiotropic therapy for pediatric patients with COVID-19, and 18 positions are used for pathogenetic therapy. In terms of frequency of occurrence, the leading positions are occupied by remdesivir and the combination of nirmatrelvir with ritonavir, as well as dexamethasone and tocilizumab. The paper emphasizes the relevance of research in the field of evaluating the effectiveness of individual treatment regimens as well as the analysis of the delayed consequences of pathology suffered in childhood under the conditions of using various approaches to pharmacotherapy.

22 January 2019 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
INI. A. Narkevich
I. A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
DSD. D. Siukaeva
D. D. Siukaeva
IPI. V. Pavlushkov
I. V. Pavlushkov
DID. O. Ivanov
D. O. Ivanov
YPYa. V. Panyutina
Ya. V. Panyutina
The aim of the study is to determine the limits of using the mathematical-statistical analysis for the evaluation of pharmacotherapy costs in pediatric inpatients diagnosed with community-acquired pneumonia. Materials and methods. The report is based on the assessment of 547 medical records of patients with community-acquired pneumonia, who underwent the treatment in four pediatric hospitals in St. Petersburg. The data array was created from a number of factors that characterize the patients’ profile (gender, duration of hospital stay, cost of therapy, number of prescribed drugs, number of affected lung segments, pathogen location, leukocyte count, and eSR). Results. Correlation analysis allowed us to identify factors contributing to the cost of pharmacotherapy (at a significance of p=0.05); those were: the duration of hospital stay (r=0.34), the number of prescribed drugs (r=0.26), and the number of affected lung segments (r=0.21). Dispersion analysis of qualitative factors (gender, location of pneumonic infiltrate) showed no significant impact of these factors on the costs or the number of prescribed drugs in the total data set. From the regression analysis, we obtained formulas for the dependence of the resulting parameters (cost of pharmacotherapy, number of prescribed drugs) on a set of independent variables. Conclusion. The treatment cost optimization in pediatric patients with community-acquired pneumonia should include the use of antibacterial drugs with proven efficacy and safety, as well as a reduction in non-necessary supporting therapy, e.g., medications aimed to correct morphological and functional changes in the respiratory system.

20 July 2022 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
DDD. D. Demchenko
D. D. Demchenko
KEKonstantin Ermolenko
Konstantin Ermolenko
YLYu. V. Lobzin
Yu. V. Lobzin
INI. A. Narkevich
I. A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
ЮМЮ. В. Матлашевская
Ю. В. Матлашевская
The paper analyzes approaches to etiotropic therapy and structural assessment of the range of drugs for the treatment of campylobacteriosis in children. The methods of content analysis, grouping, data aggregation, comparative and marketing analysis were used. The information base of the study was the State Register of Medicines, federal clinical guidelines for the provision of medical care to children with campylobacteriosis, European and American clinical guidelines, as well as instructions for the medical use of drugs.Comparative analysis showed that Russian clinical guidelines contain 15 international non-proprietary names used for the etiotropic therapy of campylobacteriosis. The analysis carried out by drug producing countries shows that the leading positions in the supply structure are occupied by Russian producers (68.26%). Structuring by dosage forms makes it possible to single out tablet positions (47.46%). At the same time, 36.47% of the range of drugs are approved for use from the age of 12, which limits the implementation of modern approaches to the rational etiotropic therapy of campylobacteriosis in pediatrics. Structural analysis of the range of pharmaceutical substances identifies a significant contribution to the structure of imports of Chinese producers (46.30%), which, in turn, justifies the prospects for import substitution. Solving the problem of improving the quality of medical care for children with campylobacteriosis determines the prospects for further research based on the principles of evidence-based medicine using the tools of mathematical-statistical and pharmacoeconomic analyses.

17 March 2026 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
МММарина Майстренко
Марина Майстренко
EME.A. Maksimtseva
E.A. Maksimtseva
ONOksana Nemyatykh
Oksana Nemyatykh
INI.A. Narkevich
I.A. Narkevich
MKMikhail Kupriyanov
Mikhail Kupriyanov
ETE.S. Terekhov
E.S. Terekhov
Objective. To assess the quality of life in pediatric patients after COVID-19. Material and methods. An observational multiple-center retrospective-prospective study included data on 107 pediatric quality of life questionnaires (QUALIN and PedsQL 4.0) and 80 pediatrician questionnaires. Statistical analysis of primary data was performed using Pandas (data preparation and processing), NumPy, SciPy, Matplotlib (statistical computing), and Seaborn (results visualization). Results. QoL scores decline after discharge in the following areas: behavior and communication (by 23.2%), ability to be alone (by 32.0%), and neuropsychic development and physical health (by 18.8%). Notably, physical functioning scores in children decreased by 20% in 2 years after discharge. The incidence of doctor visits after COVID-19 increased in cohorts of children under 1 year, 1—3 years, and 3—7 years. Consolidated QoL scores of parents showed steady increase over the study period that was generally consistent with data of QUALIN and PedsQL 4.0 questionnaires. QoL in patients with high adherence to treatment in post-hospital period was higher (p=0.0256) at the final stages of follow-up than in children who did not take the prescribed medications at discharge. Conclusion. There is decline in QoL in children in post-hospital treatment of COVID-19. The effeciveness of QoL recovery is associated with adherence to treatment after discharge.